Leading five global vaccine products by revenue 2017 and 2024

This statistic displays the top 5 global vaccine products based on their revenues worldwide in 2017, and a projection for 2024. Pfizer's pneumococcal vaccine, Prevnar 13, is expected to generate some 5.76 billion U.S. dollars in revenues by 2024. A vaccine often contains an agent that is made from a weakened form of a disease microbe, that is then used to stimulate the body's immune system to destroy and recognize the microorganism in case of later exposures.

Top vaccine products

Vaccines act as a preventive measure to improve immunity to certain diseases. Often, vaccines are created from a weakened or killed form of a microbe which allows the immune system to react and create a record of it, so that in the future, it can easily recognize these microorganisms. Vaccine use can easily help to prevent contraction of certain viruses such as influenza. However, some countries may not have easy access to vaccinations. In India, there were approximately 1.8 million deaths due to vaccine-preventable diseases as of 2013.

The global vaccination market generated 27.7 billion U.S. dollars in 2017 and is projected to total around 45 billion U.S. dollars in 2024. As of 2014, there were 18 new vaccines that were moving along the research and development pipeline for neglected diseases. Vaccines in the United States accumulated some of the world’s largest revenues, totaling 10.8 billion U.S. dollars in 2013. In comparison, Germany generated around three billion U.S. dollars at the vaccine market. Prevnar 13 and Gardasil are the top vaccines in the world, generating 5.7 billion and 2.4 billion U.S. dollars, respectively, in 2017. Prevnar 13 is marketed by Pfizer and Daewoong.

Top 5 global vaccine products based on revenue in 2017 and 2024

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

June 2018



Survey time period

as of May 2018

Supplementary notes

Statistic is ranked by 2024 revenue.
* Projected.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 / Month *
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Vaccinations in the U.S."

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.